Asif Ali smashed four sixes in the penultimate over to help Pakistan achieve a hard-fought five-wicket win over Afghanistan in the Twenty20 World Cup in Dubai on Friday.
With Pakistan needing 24 runs off the final two overs, Asif lifted paceman Karim Janat's first, third, fifth and sixth balls over the boundary to help Pakistan overhaul a tricky 148-run target.
Asif finished with 25 off just seven balls with four sixes and a single, leaving Janat and all the other Afghan players frustrated.
The win gave Pakistan a third win in as many games in Group 2 of the Super 12 stages, almost assuring a semi-final place, needing just one more win from their last two games.
Afghanistan scored a fighting 147-6 in their 20 overs with Gulbadin Naib and skipper Mohammad Nabi each scoring 35.
Pakistan skipper Babar Azam was full of praise for Asif.
"I was very confident Asif would get us out of any trouble we find ourselves in," said Babar, whose team tops the Group 2 with six points in three matches.
"Asif's hitting was clean and that's why we selected him."
Nabi was equally appreciative of Asif's hitting.
"We didn't start really well but the total on the board was decent but maybe not enough, only because of Asif," said Nabi.
Babar anchored Pakistan's innings with a 47-ball 51 but his dismissal -- bowled by spinner Rashid Khan -- turned the game on its head in the 17th over with Pakistan needing 26 off the last three overs.
Paceman Naveen-ul-Haq conceded just two runs in the 18th over and dismissed Shoaib Malik for 19 but Asif quashed all hopes of an Afghanistan win.
Pakistan's task was to handle spinners Rashid and Mujeeb Ur Rahman in their chase with the evening dew making life tough for bowlers.
Mujeeb dismissed Mohammad Rizwan (eight) while Nabi accounted for Fakhar Zaman (30) before Rashid's wickets of Mohammad Hafeez (10) and Babar.
Earlier, Gulbadin Naib and Nabi lifted Afghanistan from a wobbly start.
Naib smashed a 25-ball 35 not out while Nabi scored an undefeated 32-ball 35 as they helped Afghanistan recover from 76-6 with an unbroken seventh wicket stand of 71 after they won the toss and batted.
All six top Afghanistan batsmen were caught playing rash shots but Nabi and Naib added 54 runs in the last five overs to give their team a fighting total.
Naib hit two fours and a six off paceman Hasan Ali to take 21 off the 18th over and the pair scored 15 in the 19th bowled by Haris Rauf.
Naib's knock had four boundaries and a six while Nabi hit five boundaries.
Left-arm spinner Imad Wasim was the pick of Pakistan's bowlers with 2-25, dismissing dangerous opener Hazratullah Zazai for a five-ball duck.
Najibullah Zadran (22) and Janat (15) were other contributors.
Pakistan kept the same eleven which beat India and New Zealand in their first two matches while Afghanistan were also unchanged from their first game rout of Scotland.
The top two teams from each of the two groups will qualify for the semi-finals.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.